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Dr Joseph C. Cleveland (Aurora, Colo). The management of
an allosensitized potential cardiac transplant recipient remains
highly anecdotal and center specific as outlined in the presentation.
In essence, each center possesses its own witch’s brew—the treat-
ment to reduce PRA levels, including plasmapheresis, intravenous
immunoglobulin, and some novel newer agents.
This analysis by Schaffer and colleagues is important and seeks
to provide guidance for managing these allosensitized patients.
The findings of the present study are novel and important. Both
the peak PRA level and the inability to reduce the PRA level by
less than 20% leads to an inferior allograft survival, at least in
this UNOS registry over a 10-year period. I applaud the authors’
use of propensity matching to try to equal as much as you can,
make the patient comorbidities as equitable as possible. I have 3
questions.
My first question pertains to the obvious choice of time periods
for analysis as you outlined. The way that we now analyze PRA in
the cell-based Luminex (Austin, Tex) technology is so different
than in the prior era of 1987-2004. I acknowledge your desire to
keep a homogeneous patient population, but why not focus on
the period of transplantation that we are now dealing with, from
2004 to 2010. What made you want to look from 1987 to 2004?
What about a patient who has a PRA of a mean fluorescent inten-
sity of 2000 units in one of these cell-based technologies: Do you
think your data really will help us deal with that type of patient?
Dr Schaffer (Stanford, Calif). To be honest, the real reason we
started this study of the ‘‘older’’ era was to simplify our analysis
and to serve as a starting point for future study. If we could prove
that a reduction in MHC class I PRA levels before transplant inde-
pendently improved long-term survival in the ‘‘older era’’ cohort,
we would have a good starting point to try and differentiate
between the different assays used in the more recent PRA era.
This study serves as our starting point. We now know that
a PRA reduction independently improves post-transplantation sur-
vival. Now we have to try and figure out how it works in the more
recent era. Factors that complicate this analysis are that more
recent technologies assess both class 1 and 2 PRA percentages.
Now we can try and assess whether a reduction in a particular
MHC class matters more, and to try to determine how the different
methods of measuring PRA level in the more recent era affects the
documented levels of PRA activity.
Dr Cleveland. Fair enough. So you report your primary end
graft is allograft survival. One of the potential risks to aggressive
desensitization protocols is the occurrence of excess mortality
after transplantation that is due to infectious causes. Was overall
patient survival between these groups analyzed? Do you have
those data?ery c February 2013
Schaffer et al Cardiothoracic TransplantationDr Schaffer. I do not have the curve to show you, but from our
experience the post-transplant graft survival and mortality curves
are similar. The study’s primary end point is a composite of all
cause mortality and graft failure, which we believe is the most
appropriate end point for this analysis.
Dr Cleveland. You do not think you saw an excess signal indi-
cating mortality from infectious causes at least as best you could?
Dr Schaffer. Our study did not specifically assess causes of
death, only time to graft failure or death.
DrCleveland. Last, as you acknowledge, there were not a lot of
VAD recipients in this cohort, but one of the principal methods
whereby patients develop elevated PRA levels are those that
require a left VAD as a bridge to transplantation. The Johns Hop-
kins group published an analysis from the same UNOS thoracic
registry. They stratified left VAD recipients with PRA of 0% versus
25% and observed no difference in rejection rates for the first year
after cardiac transplantation and no difference in overall patient
survival. Can you put your study in perspective with their data?
How do your data and analysis perhaps differ from their study
and other ways that patients might be treated differently to desen-
sitize them if they are a VAD recipient?
Dr Schaffer. I suspect the Hopkins group, when they were cre-
ating their study, probably ran into the same troubles that we did in
trying to decide how to differentiate between a peak and a most
recent PRA level when you have 2 different values for the 2 differ-
ent MHC classes. I suspect that is why they limited their analysis to
just the most recent PRA levels. As to differentiating ours, I think
our analysis gives you a good idea what to expect for the non-VAD
recipient, and theirs obviously is limited to VAD recipients. Their
study does make the important point as to how useful PRA levels
are in the population with VADs. We hope to assess this in our
future work assessing the more recent era.
Dr Cleveland. One last minor follow-up question in terms of
the Kaplan–Meier curves. It looks like the initial first year is really
where this difference is. Are those slopes truly similar or is there
a late risk that these patients might incur by having elevated PRA?The Journal of Thoracic and CaDr Schaffer. In our analysis there is a statistically significant
difference, but it is tiny. I forget the event rate per se, but it is so
small as to not be clinically relevant. All of that risk really comes
in the first year and most in the first 6 months.
Dr Cleveland. Nice presentation.
Dr Timothy Icenogle (Spokane, Wash). I rise to translate for
the audience what I think is an enormous contribution to medical
science. What these therapies are aimed at are basically deleting
immunologic memory, that is, to delete the memory cells of a pre-
vious exposure to somebody else’s tissues. The new studies that
you described are highly sensitive and specific. What you have
shown is that by deleting immunologic memory or at least a por-
tion of immunologic memory, there has been a reduction in bad
outcomes in transplantation. This translates well beyond the
world of transplantation to the world of autoimmune diseases,
including type 1 diabetes, amyotrophic lateral sclerosis, multiple
sclerosis, and traumatic chronic encephalopathy. If we are able to
delete immunologic memory, and in the world of transplantation
led by young surgeons such as yourself, we can now explore
ways to delete immunologic memory, this will have huge impli-
cations for the rest of medicine. In your evaluation of all of these
therapies, there has been considerable improvement. In your
studies, were you able to find any therapies that were perhaps
more successful than other therapies in deleting immunologic
memory?
Dr Schaffer. You have identified the biggest problem with our
study. I must not have made it clear during my talk, but the huge
limitation of the UNOS database is that we do not have the under-
lying treatment as to what these patients received. We just know
that they had a high PRA level and that it was substantially reduced
at the time of transplant. I wish I had those data (treatment type).
To my knowledge, those data are not prospectively collected in the
UNOS database. That is obviously the key to this, and we do not
have that right now, but in newer data sets in the more recent era
we do have some of those data. We will be trying to assess that
in future studies.rdiovascular Surgery c Volume 145, Number 2 565
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